On April 22, 2021 MonTa Biosciences, a Danish clinical stage biotech company located in Copenhagen, reported the first patient has been dosed with Monta Bioscienes MBS8 in a Phase I clinical trial (Press release, MonTa Biosciences, APR 22, 2021, View Source [SID1234578399]). Patients with solid tumors are enrolled at two danish hospitals in Copenhagen, Rigshospitalet and Herlev Hospital. 30-50 patients will be enrolled over the next 18 months.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
MonTa Biosciences lead candidate MBS8 was administered intravenously to the first patient in the trial at Rigshospitalet in Copenhagen on Wednesday, April 21. The primary objective of the trial is to evaluate the safety of multiple escalating doses of MBS8 for patients with advanced solid tumours and to establish the maximum tolerated dose (MTD/recommended Phase 2 dose (RP2D). The effects on biomarkers and objective tumor response in the patients will also be assessed.
MBS8 treatment is an innovative way to stimulate the immune system to help the body fight cancer. MBS8 is a nanoparticle that contains an immune stimulating compound called a TLR7 agonist that activate certain types of immune cells which are able to enter tumor tissue from the blood and kill tumor cells. After weeks of treatment MBS8 is also able to stimulate immune memory T-cells to recognize and eliminate cancer cells, which is of particular interest to cancer patients with metastatic disease, where there is a huge unmet medical need for better treatment.
MonTa Biosciences’ CEO, Simon S Jensen said "We are very excited to have the first patient dosed with MBS8 and hope the drug will demonstrate to be safe for the patients, and even more important also have an impact on their cancer. With the new mode of action for MBS8, which has never been seen for any cancer drug before, we have high expectations to MBS8 and hope we already in this phase I will be able to help patients in need. It is quite rare to see drugs acting as monotherapy on the immune system as efficiently as MBS8, often cancer immunotherapy treatments are combined with other treatments to enhance their therapeutic activity."